Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer

Cardiovascular risks of androgen deprivation therapy.

Prostate adenocarcinoma is the most common cancer type in the male sex after skin cancer. Among the several types of treatment for prostate cancer, the androgen deprivation therapy has been highly recommended in patients with metastatic or locally advanced disease, which probably results in increased survival. However, the androgen deprivation is the cause of several adverse effects. Complicati...

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Androgen deprivation therapy for prostate cancer.

CONTEXT Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE To review systematically the evidence on the risk...

Androgen Deprivation for Prostate Cancer

The beneficial effects of androgen deprivation on prostate cancer have been known for more than a half century, based on work demonstrating the androgen dependency of prostate tumor cells. Androgen deprivation therapy (ADT), initially in the form of bilateral orchiectomy, has accordingly long been a mainstay for the palliation of metastatic prostate cancer. For most of its history, concerns abo...